Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can regional data improve bone marrow transplant results for blood cancers?

NCT ID NCT07823946

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers at Assiut University are studying adults with blood cancers who receive an autologous hematopoietic stem cell transplant, a procedure that uses a patient's own stem cells. The study follows 123 participants to measure survival, progression-free survival, complications such as infections and organ toxicity, and patient satisfaction. The goal is to identify which factors are linked to better or worse transplant outcomes in this region.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous hematopoietic stem cell transplantation
What this could lead to
If the study identifies factors that predict better transplant outcomes, doctors in Upper Egypt and similar regions could refine how they select patients and manage complications after the procedure.
What could go wrong
This is a single-region observational study with 123 participants, so its findings may not apply to other hospitals or populations. It tracks outcomes without testing a new treatment, so it cannot prove that any specific approach causes better results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 123 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All consecutive adult patients with hematological malignancies who underwent autologous hematopoietic stem cell transplantation at the Bone Marrow Transplantation Unit, Assiut University Hospitals, during the study period and fulfilled the eligibility criteria.

Ages

18 to 100 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Adult patients (≥18 years) with a confirmed diagnosis of a hematological malignancy. 2.Patients undergoing their autologous hematopoietic stem cell transplantation (ASCT). 3-willingness to participate in the study Exclusion Criteria: \- 1.Patients undergoing allogeneic hematopoietic stem cell transplantation. 2.Patients with uncontrolled active infection or severe organ dysfunction that contraindicates transplantation. 3.Patients with incomplete clinical data or who withdraw consent during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autologou are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autologou Bone marrow transplant complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.